Retrophinis a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable patient options. The company’s lead compound, RE-021, is scheduled to begin enrollment in a potentially pivotal phase 2 clinical trial for FSGS during the first half of 2013. For more information, visit the company’s Web site: http://www.retrophin.com
Let us hear your thoughts below: